12052606 (P.T.A.B. Oct. 1, 2015)

Boehringer Ingelheim Pharmaceuticals, Inc.v.Genentech, Inc.

Patent Trial and Appeal BoardOct 1, 2015

12052606 (P.T.A.B. Oct. 1, 2015)

Trials@uspto.gov Paper 18 571-272-7822 Entered: October 1, 2015 UNITED STATES PATENT AND TRADEMARK OFFICE ____________ BEFORE THE PATENT TRIAL AND APPEAL BOARD ____________ BOEHRINGER INGELHEIM INTERNATIONAL GMBH AND BOEHRINGER INGELHEIM PHARMACEUTICALS, INC., Petitioner, v. GENENTECH, INC., Patent Owner. ____________ Case IPR2015-00417 Patent 7,976,838 B2 ____________ Before FRANCISCO C. PRATS, ERICA A. FRANKLIN, and SHERIDAN K. SNEDDEN, Administrative Patent Judges. FRANKLIN, Administrative Patent Judge. JUDGMENT Termination of the Proceeding 37 C.F.R. § 42.73 IPR2015-00417 Patent 7,976,838 B2 2 On December 15, 2014, Boehringer Ingelheim International GmbH and Boehringer Ingelheim Pharmaceuticals, Inc. (collectively, “Petitioner”) filed a Petition requesting an inter partes review of claims 1–14 of U.S. Patent No. 7,976,838 B2 (Ex. 1001, “the ’838 patent”). Paper 3. Genentech, Inc. (“Patent Owner”) filed a Preliminary Response to the Petition. Paper 9. On July 14, 2015, we instituted an inter partes review of claims 1–14 of the ’838 patent. Paper 11. On September 29, 2015, Petitioner filed a Request for Adverse Judgment for Abandonment of the Contest under 37 C.F.R. § 42.73(b)(4) (“Request for Adverse Judgment”). Paper 17. Pursuant to 37 C.F.R § 42.73(b)(4), the Board construes an abandonment of the contest as a request for adverse judgment against the party abandoning the contest. A party may request judgment against itself at any time during a proceeding. 37 C.F.R § 42.73(b). Accordingly, it is hereby ORDERED that Petitioner’s Request for Adverse Judgment for Abandonment of the Contest under 37 C.F.R § 42.73(b)(4) with respect to claims 1–14 of the ’838 patent is GRANTED; ORDERED that judgment is entered against Petitioner; and FURTHER ORDERED, that the proceeding is TERMINATED. IPR2015-00417 Patent 7,976,838 B2 3 PETITIONER: Siegmund Gutman BI-USPTO_Comm@proskauer.com Anthony Coles acoles@proskauer.com Gerald Worth gworth@proskauer.com Colin Cabral ccabral@proskauer.com Amy Hayden ahayden@proskauer.com PATENT OWNER: Jeffrey Kushan IPRNotices@sidley.com James High jhigh@sidley.com Gary Frischling Genetech/rituxanIPR@irell.com Keith Orso Genetech/rituxanIPR@irell.com

Boehringer Ingelheim Pharmaceuticals, Inc. v. Genentech, Inc.